55 completed, 19 unknown, 5 withdrawn, 4 recruiting. 91 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 91 | Completed 55, Unknown 19, Withdrawn 5, Recruiting 4, Terminated 3, Not yet recruiting 2, Active not recruiting 1, Enrolling by invitation 1, Suspended 1 |
Follow Losartan: new trials by email Literature Review of Losartan trials Research Report on Losartan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction Losartan, Placebo - ACL Injury, ACL Reconstruction | Phase 4 | Not yet recruiting | Rush University Medical Center | 144 | 2026-08-01 | 2025-12-15 |
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB Lenvatinib + losartan - Carcinoma, Hepatocellular | Phase 4 | Not yet recruiting | Second Affiliated Hospital of Xi'an Jiaotong University | 56 | 2025-10-01 | 2025-09-16 |
| Effect of Losartan on the Neurohumoral Axis and Ventricular Remodeling of Patients With Severe Aortic Regurgitation Undergoing Valve Surgery. Losartan 50 mg, Placebo - Heart Valve Diseases, Left Ventricle Remodeling | Phase 4 | Recruiting | Vitor Emer Egypto Rosa | 60 | 2025-07-01 | 2025-08-01 |
| Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty Losartan - Arthrofibrosis of Knee | Phase 4 | Withdrawn | NYU Langone Health | 2024-07-01 | 2024-09-23 | |
| Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty Losartan - Arthrofibrosis | Phase 4 | Withdrawn | NYU Langone Health | 2023-09-01 | 2023-12-01 | |
| A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome Telmisartan, Losartan - Essential Hypertension, Metabolic Syndrome | Phase 4 | Unknown | Chong Kun Dang Pharmaceutical | 116 | 2023-06-01 | 2023-05-06 |
| Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. Corticosteroid, Renin-angiotensin sytem blockers, Sodium-glucose cotransporter 2 inhibitor - Glomerulonephritis, Immunoglobulin A Nephropathy | Phase 4 | Recruiting | Fondazione Schena | 878 | 2023-05-01 | 2025-04-02 |
| Efficacy and Safety of Telmisartan Compared With Losartan telmisartan, Losartan - Diabetic Nephropathies, Hypertension | Phase 4 | Unknown | Chong Kun Dang Pharmaceutical | 98 | 2023-04-19 | 2024-05-28 |
| Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies Losartan Potassium - Uric Acid Nephropathy | Phase 4 | Completed | Hospital General de Niños Pedro de Elizalde | 40 | 2022-07-01 | 2025-09-15 |
| Non-Inferiority Study of Aliskiren vs Losartan in the Treatment of Hypertension With Hyperuricemia Aliskiren, Losartan - Hypertension,Essential, Hyperuricemia | Phase 4 | Completed | Hansung University | 66 | 2021-05-01 | 2024-12-05 |
| Secondhand Tobacco Smoke and Cardiovascular Disease Losartan, Placebo - Cardiovascular Diseases, Hypertension | Phase 4 | Recruiting | University of California, San Francisco | 100 | 2021-03-30 | 2026-08-19 |
| Renohemodynamic Effects of Combined empagliflOzin and LosARtan Empagliflozin 10 MG, Losartan 50Mg Tab, Placebo - Diabetes Mellitus, Type 2, Diabetic Kidney Disease | Phase 4 | Completed | Amsterdam UMC, location VUmc | 24 | 2020-11-04 | 2021-10-08 |
| Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Angiotensin Receptor Blockers, Placebo - Coronavirus Disease 2019, COVID-19 | Phase 4 | Completed | The George Institute | 787 | 2020-06-19 | 2022-03-17 |
| Coronavirus (COVID-19) ACEi/ARB Investigation Thiazide or Thiazide-like diuretics, Calcium Channel Blockers, ACE inhibitor - Hypertension, COVID-19 | Phase 4 | Suspended | National University of Ireland, Galway, Ireland | 2414 | 2020-04-30 | 2020-06-30 |
| Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection Losartan - SARS-CoV Infection | Phase 4 | Completed | Sharp HealthCare | 31 | 2020-03-27 | 2021-05-26 |
| Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Peritoneal Dialysis Patients Spironolactone, Losartan - End Stage Renal Disease, Peritoneal Dialysis | Phase 4 | Unknown | Chiang Mai University | 84 | 2019-10-01 | 2019-09-04 |
| Phase 4 Study of the Efficacy of Losartan Based Therapy in Hypertensives With and Without Diabetes Losartan 50Mg Tab, Losartan/Hydrochlorothiazide 50 Mg-12.5 Mg ORAL TABLET, Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET - Diabetes Mellitus, Hypertension | Phase 4 | Withdrawn | The University of The West Indies | 2019-06-01 | 2020-09-03 | |
| Nighttime Losartan in Continous Ambulatory Peritoneal Dialysis (NVCAPD) Losartan - Hypertension,Nephropathy | Phase 4 | Unknown | Fifth Affiliated Hospital, Sun Yat-Sen University | 68 | 2018-12-01 | 2018-11-05 |
| Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease Amlodipine 5mg, Losartan, Losartan and Amlodipine - Aortic Stenosis, Aortic Regurgitation | Phase 4 | Completed | Hanmi Pharmaceutical Company Limited | 128 | 2018-10-18 | 2022-09-15 |
Showing 20 of 91. Sign in to see all of them.
Hypertension (40) · Essential Hypertension (6) · Diabetes Mellitus (5) · Diabetic Nephropathies (5) · Proteinuria (5) · Cardiovascular Diseases (4) · Diabetes Mellitus, Type 2 (4) · Heart Failure (4) · Insulin Resistance (4) · Metabolic Syndrome (4) · COVID-19 (3) · Glomerulonephritis, IGA (3) · Kidney Diseases (3) · Pulmonary Disease, Chronic Obstructive (3) · Aortic Valve Insufficiency (2)
Organon and Co (6) · Boehringer Ingelheim (4) · Chong Kun Dang Pharmaceutical (2) · Chulalongkorn University (2) · Daiichi Sankyo (2) · Hanmi Pharmaceutical Company Limited (2) · NYU Langone Health (2) · University of Pavia (2) · University of Sao Paulo (2) · AHEPA University Hospital (1) · Aarhus University Hospital (1) · Abbott (1) · Amsterdam UMC, location VUmc (1) · Baker Heart and Diabetes Institute (1) · Baylor Research Institute (1)
United States (23) · Brazil (6) · South Korea (6) · Italy (5) · China (4) · Thailand (4) · Japan (3) · Spain (3) · Argentina (2) · Australia (2) · Austria (2) · Canada (2) · Denmark (2) · Mexico (2) · Netherlands (2)
Joshua Rozell, MD (2) · Talerngsak Kanjanabuch, Assist. Prf. (2) · Ahmed R. EL-Nahas, MD (1) · Alberto Zanchetti, MD (1) · Alejandro Balestracci, MD, Ph. D. (1) · Alireza Esteghamati, MD (1) · Amr G. Gendya, MD (1) · Andrew Bi, MD (1) · Annette Dam, MD (1) · Antonio P Barretto, Ph.D. (1) · Ashkan Eftekhari, MD, PhD (1) · BeomSeok Kim, M.D, Ph.D (1) · Bertram Kasiske, M.D. (1)
PMID 38682786, PMID 32905623, PMID 36398903, PMID 38299639, PMID 38770818, PMID 39082471, PMID 11593107, PMID 12937228, PMID 15851648, PMID 16281062, PMID 16988754, PMID 17130190, PMID 17324745, PMID 17533019, PMID 17978307, PMID 18335252, PMID 18475165, PMID 18496508, PMID 18670416, PMID 19571790, PMID 19571791, PMID 19628656, PMID 19949604, PMID 20827028, PMID 20966122, PMID 21606384, PMID 21852672, PMID 21861845, PMID 22075320, PMID 22763801, PMID 22981148, PMID 23490405, PMID 23965522, PMID 24029421, PMID 24457184, PMID 24838894, PMID 25018935, PMID 25480673, PMID 25585823, PMID 25622599, PMID 26414380, PMID 26465872, PMID 26630142, PMID 27548072, PMID 28341274, PMID 28395659, PMID 28763548, PMID 28879040, PMID 29580174, PMID 29931555
2009 (1), 2023 (1), P50HL084945 (1), R01DK060706 (1), R01HL133240 (1), R01HL139365 (1), UL1TR003167 (1)